The
California
Institute of Molecular Medicine (CIMM) was
founded in 1997 to provide "scientific space" for Zaki Salahuddin to
develop: a compliment of scientists to perfect the methodology of successfully
culturing hepatitis-C virus (HCV) invitro, a rational
therapy to treat the infection, and answer several important questions that
remain unanswered in the field today. Since
it’s founding, CIMM has made significant progress in the technology due to the contributions
of Salahuddin.
Thus
far CIMM has accomplished the following:
·
Developed a means to isolate a self-replicating strain of HCV. CIMM isolate is
believed to be
the only such strain of (HCV) that
can live and reproduce in vitro. Such a strain can be utilized to
test and identify potential anti-HCV drugs in the laboratory without the
need for expensive and time-consuming live animal trials.
·
Using the self-replicating HCV, CIMM has identified a substance (designated
XHC) that has shown efficacy in treating HCV in vitro and could be a safe
and effective anti-HCV drug and a substantial improvement over existing
anti-HCV therapies. XHC could also potentially be effective against
HIV.
·
Separately, CIMM has developed a Kupffer’s Cell therapy designed to regenerate
liver functions (actually replenish healthy liver cells) in liver patients,
thereby prolonging liver function while the patient is awaiting a liver
transplant or other treatment. CIMM has filed a provisional patent application
for this therapy in 2000.
·
As a by-product of its viral research, CIMM has identified a substance
(designated XFL) that has shown efficacy in treating feline leukemia virus
infection of cats. Cat leukemia is a
pervasive animal disease that presently has no cure.
Objective
Market Strategy
Company's Future
Senior Management
Scientific Advisory Board
People at Work
|
